donanemab

The Alzheimer’s Treatment Landscape: Leqembi vs. Donanemab
The Alzheimer’s Treatment Landscape: Leqembi vs. Donanemab
BioSpace
Alzheimer's disease
Eli Lilly
Biogen
Eisai
Leqembi
donanemab
Flag link:
The 10 highest value R&D projects in biopharma
The 10 highest value R&D projects in biopharma
Fierce Biotech
R&D
biotech
Merck
sotatercept
Daiichi Sankyo
AstraZeneca
Dato-DXd
Novo Nordisk
CagriSema
Eli Lilly
donanemab
Karuna Therapeutics
Zai Lab
KarXT
Moderna Therapeutics
mRNA-1647
Novartis
iptacopan
Madrigal Pharmaceuticals
resmetirom
Cytokinetics
aficamten
Roche
Chugai
tiragolumab
Flag link:
Lilly’s donanemab flaunts strong clinical profile, ready to compete with Leqembi
Lilly’s donanemab flaunts strong clinical profile, ready to compete with Leqembi
Clinical Trials Arena
Eli Lilly
donanemab
Eisai
Biogen
Leqembi
Alzheimer's disease
Flag link:
Lilly shares full pivotal data on Alzheimer’s drug, revealing how it shapes up against Leqembi
Lilly shares full pivotal data on Alzheimer’s drug, revealing how it shapes up against Leqembi
Fierce Biotech
Eli Lilly
Alzheimer's disease
clinical trials
FDA
donanemab
Flag link:
Alzheimer’s Drug Market To Hit $13 Billion As FDA Approvals And Insurance Coverage Escalate
Alzheimer’s Drug Market To Hit $13 Billion As FDA Approvals And Insurance Coverage Escalate
Forbes
Alzheimer's disease
FDA
insurance
Leqembia
Biogen
Eisai
Eli Lilly
donanemab
Flag link:
Alzheimer’s doctors see promise, limits in Lilly’s latest drug data
Alzheimer’s doctors see promise, limits in Lilly’s latest drug data
BioPharma Dive
Eli Lilly
donanemab
Alzheimer's disease
physicians
Flag link:
Lilly's Donanemab Data Energizes Alzheimer’s Sector, Safety Concerns Remain
Lilly's Donanemab Data Energizes Alzheimer’s Sector, Safety Concerns Remain
BioSpace
Eli Lilly
Alzheimer's disease
donanemab
Flag link:
Lilly drug slows Alzheimer’s decline in large study
Lilly drug slows Alzheimer’s decline in large study
BioPharma Dive
Eli Lilly
donanemab
clinical trials
Alzheimer's disease
Flag link:
Biogen isn’t concerned about competing with Eli Lilly in the Alzheimer’s drug space, CEO says
Biogen isn’t concerned about competing with Eli Lilly in the Alzheimer’s drug space, CEO says
CNBC
Biogen
earnings
Pharma CEOs
Chris Viehbacher
Eli Lilly
Alzheimer's disease
Leqembi
donanemab
Flag link:
Some Experts Say FDA Made the Right Call on Lilly's Donanemab
Some Experts Say FDA Made the Right Call on Lilly's Donanemab
BioSpace
Eli Lilly
FDA
Alzheimer's disease
donanemab
Flag link:
This Week at FDA: Pallone pushes for greater ClinicalTrials.gov enforcement, FDA rejects Eli Lilly Alzheimer’s drug, and more
This Week at FDA: Pallone pushes for greater ClinicalTrials.gov enforcement, FDA rejects Eli Lilly Alzheimer’s drug, and more
RAPS.org
FDA
regulatory
clinical trials
clinicaltrials.gov
Eli Lilly
donanemab
Medtronic
BeiGene
Seagen
Flag link:
Innovative Trial Design may have Cost Lilly’s Donanemab Accelerated Approval
Innovative Trial Design may have Cost Lilly’s Donanemab Accelerated Approval
BioSpace
Eli Lilly
donanemab
FDA
clinical trials
Alzheimer's disease
clinical trial design
Flag link:
Eli Lilly says U.S. FDA rejects accelerated approval for Alzheimer's drug
Eli Lilly says U.S. FDA rejects accelerated approval for Alzheimer's drug
Yahoo/Reuters
Eli Lilly
FDA
donanemab
Alzheimer's disease
Flag link:
Alzheimer’s disease trials: How does Lilly’s donanemab compare to lecanemab?
Alzheimer’s disease trials: How does Lilly’s donanemab compare to lecanemab?
Clinical Trials Arena
clinical trials
Alzheimer's disease
Eisai
Biogen
Eli Lilly
Leqembi
lecanemab
donanemab
Flag link:
JPM23: Amid launch spree, Eli Lilly expects revenue growth at the 'high end of the industry,' CFO says
JPM23: Amid launch spree, Eli Lilly expects revenue growth at the 'high end of the industry,' CFO says
Fierce Pharma
JPMHC 2023
Eli Lilly
pertibrutinib
donanemab
mirikizumab
lebrikizumab
Flag link:
5 FDA decisions to watch in the first quarter
5 FDA decisions to watch in the first quarter
BioPharma Dive
FDA
Eli Lilly
donanemab
Alzheimer's disease
Menareni
Elacestrant
breast cancer
Biomarin
Roctavian
hemophilia A
Acadia Pharmaceuticals
trofinetide
Rett Syndrome
Gilead Sciences
Trodelvy
Flag link:
Eli Lilly’s 2023 guidance: Up to 4 new drugs on the way
Eli Lilly’s 2023 guidance: Up to 4 new drugs on the way
Medical Marketing and Media
Eli Lilly
donanemab
mirikizumab
lebrikizumab
pirtobrutinib
Flag link:
Lilly’s Donanemab Shines vs. Aduhelm in First Active Comparator Study
Lilly’s Donanemab Shines vs. Aduhelm in First Active Comparator Study
BioSpace
Eli Lilly
donanemab
clinical trials
Aduhelm
Biogen
Alzheimer's disease
Flag link:
Lilly powers through final stretch in critical Alzheimer's race
Lilly powers through final stretch in critical Alzheimer's race
Fierce Biotech
Eli Lilly
Alzheimer's disease
donanemab
lecanemab
Eisai
Flag link:
A Biotech Breakthrough Means Big Gains for These 2 Stocks
A Biotech Breakthrough Means Big Gains for These 2 Stocks
Motley Fool
Eli Lilly
Biogen
Alzheimer's disease
lecanemab
donanemab
Flag link:

Pages